Vittoria Biotherapeutics is presenting its Phase 1 clinical trial results for VIPER-101, a gene-edited CAR-T therapy targeting CD5-positive T-cell lymphoma, at the 2025 ASCO Annual Meeting. This trial marks the first clinical use of Vittoria’s Senza5™ platform, a novel CAR-T engineering and manufacturing process designed to improve treatment effectiveness. The open-label study aims to evaluate the safety, preliminary efficacy, and establish the recommended Phase 2 dose of VIPER-101 in patients with relapsed or refractory CD5-positive T-cell non-Hodgkin lymphoma.
This research is particularly crucial because T-cell lymphomas are a challenging group of blood cancers with limited treatment options. Current therapies often fall short due to relapse, refractory disease, and significant toxicity. The introduction of a potentially more effective and safer CAR-T therapy specifically targeting CD5, a protein present on most T-cell lymphoma cells, offers a new avenue for patients who have exhausted other treatment options. The novel Senza5™ platform could represent a significant step forward in CAR-T cell engineering, potentially improving efficacy and durability of treatment response.
Technically, VIPER-101 utilizes a dual-population approach and gene editing to abrogate CD5-mediated immunosuppression, thereby enhancing T-cell potency. The Senza5™ platform, central to this therapy, incorporates a five-day manufacturing process aimed at maximizing the stemness and durability of the engineered T cells. This faster production time may be key to improving accessibility and affordability of CAR T cell therapy. The Phase 1 trial will provide critical data on safety and efficacy, paving the way for further clinical development.
The outcomes of this Phase 1 trial will heavily influence the future direction of VIPER-101 and the Senza5™ platform. Positive results could lead to a rapid advancement into Phase 2 trials and potentially accelerate the development of other CAR-T therapies utilizing this technology. This could usher in a new era in the treatment of T-cell lymphomas and potentially other cancers, offering patients a more targeted and effective therapeutic option. Furthermore, successful development of the Senza5™ platform could broadly impact the field of cellular immunotherapy, improving the overall efficacy and accessibility of CAR-T therapies.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
